SEC Form 4 · accession 0001093557-18-000199
DEXCOM INC · DXCM
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Andrew K Balo
Officer — EVP, Reg. Strategy, Clinical
Period of report
Sep 10, 2018
Accepted (ET)
Sep 12, 2018 · 9:21 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001093557
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2 | Sep 10, 2018 | S | 2,407 | $143.7552 | D | 96,285 | D | |
| Common StockF1,F2 | Sep 10, 2018 | S | 3,180 | $143.7552 | D | 93,105 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.
- F2Included in this number are 59,217 unvested restricted stock units, 38,502 of which were granted on March 8, 2018 and shall vest through March 8, 2021, 14,381 of which were granted on March 8, 2017 and shall vest through March 8, 2020 and 6,334 of which were granted on March 8, 2016 and shall vest through March 8, 2019.